ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders.
ProQR Therapeutics has raised $59.2M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
ProQR Therapeutics's investors include Eli Lilly, Sofinnova Partners, Pontifax, Rett Syndrome Research Trust.
ProQR Therapeutics is headquartered in Leiden, The Netherlands.
ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders.
ProQR Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ProQR Therapeutics — Funding & Investors." VCBacked, June 25, 2026, https://www.vcbacked.co/company/proqr-therapeutics. Accessed November 13, 2026.
VCBacked. (2026). ProQR Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/proqr-therapeutics
{{cite web |title=ProQR Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/proqr-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at ProQR Therapeutics? Request a listing update